Darusentan

Darusentan
Darusentan
Systematic (IUPAC) name
(2S)-2-(4,6-Dimethoxypyrimidin-2-yl)oxy-3-methoxy-3,3-di(phenyl)propanoic acid
Clinical data
Pregnancy cat.  ?
Legal status  ?
Routes Oral
Pharmacokinetic data
Metabolism Hepatic
Half-life 12.5 hours
Identifiers
CAS number 171714-84-4 YesY
ATC code None
PubChem CID 177236
UNII 33JD57L6RW N
ChEMBL CHEMBL23261 N
Chemical data
Formula C22H22N2O6 
Mol. mass 410.42 g/mol
SMILES eMolecules & PubChem
 N(what is this?)  (verify)

Darusentan (LU-135252; HMR-4005) is a endothelin receptor antagonist. Gilead Colorado, a subsidiary of Gilead Sciences,[1] under license from Abbott Laboratories, is developing darusentan for the potential treatment of uncontrolled hypertension.

In June 2003, Myogen licensed the compound from Abbott for its application in the cancer field.[2]

In May 2007, a randomized, double-blind, active control, parallel assignment, safety and efficacy phase III trial was initiated in subjects who had completed the maintenance period of the DAR-312 study.

References

  1. ^ Gilead Sciences
  2. ^ Thomson Pharma
Stub icon This pharmacology-related article is a stub. You can help Wikipedia by expanding it.